orforglipron semaglutide comparison Lilly oral GLP-1 phase 3 weight loss trial In a phase III trial,

Compulsive use, marked by an inability to abstain or limit intake in spite of awareness of harmful outcomes, is a defining characteristic of substance use disorders (SUDs) (Health et al., 1988

While undergoing treatment a child should drink more fluids

This raises a critical question: do GLP-1 agonists have any direct effects (positive or negative) on hormone production or sperm parameters independent of weight loss

Chen B, Yu X, Horvath-Diano C, Ortuno MJ, Tschop MH, Jastreboff AM, et al

Commercial insurances are unlikely to cover it and MediCare and MediCal do not cover it

The acetazolamide monotherapy group was compared with the combined therapy group